Currently, Denali Therapeutics Inc [DNLI] is trading at $11.47, down -1.12%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The DNLI shares have lost -6.67% over the last week, with a monthly amount drifted -23.28%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Deutsche Bank started tracking the stock with Buy rating on February 11, 2025, and set its price target to $31. On January 07, 2025, Robert W. Baird initiated with a Outperform rating and assigned a price target of $31 on the stock. William Blair started tracking the stock assigning a Outperform rating. Stifel upgraded its rating to a Buy but $37 remained the price target by the analyst firm on December 16, 2024. In a note dated October 07, 2024, Cantor Fitzgerald downgraded an Neutral rating on this stock.
This stock has fluctuated between a low of $10.57 and a high of $33.33 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $38.5 within the next 12 months. Denali Therapeutics Inc [NASDAQ: DNLI] shares were valued at $11.47 at the most recent close of the market. An investor can expect a potential return of 235.66% based on the average DNLI price forecast.
Analyzing the DNLI fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.31 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.03 points at the first support level, and at 10.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.20, and for the 2nd resistance point, it is at 12.92.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Denali Therapeutics Inc [NASDAQ:DNLI] is 8.46. Further, the Quick Ratio stands at 8.46, while the Cash Ratio is 1.71.
Transactions by insiders
Recent insider trading involved Ho Carole, Chief Medical Officer, that happened on Jan 06 ’25 when 12255.0 shares were sold. Chief Medical Officer, Ho Carole completed a deal on Jan 07 ’25 to sell 2907.0 shares. Meanwhile, COFO and Secretary Schuth Alexander O. sold 12255.0 shares on Jan 06 ’25.
